Zivo Bioscience, Inc.
ZIVOOTCHealthcare · Biological Products, (No Diagnostic Substances) · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $157,220 | $27,650 | $0 | $0 | $20,000 | $0 |
| Operating income | −$13.4M | −$7.3M | −$8.7M | −$8.6M | −$8.6M | −$8.4M |
| Net income | −$13.4M | −$7.8M | −$8.7M | −$8.8M | −$9.1M | −$11.5M |
| Total assets | $1.6M | $555,715 | $2.1M | $9.0M | $220,179 | $369,393 |
| Total liabilities | $2.2M | $2.8M | $2.1M | $2.9M | $11.5M | $8.7M |
| Equity | −$514,897 | −$2.2M | −$10,622 | $6.0M | −$11.3M | −$8.3M |
| EPS (diluted) | $-4.23 | $-4.60 | — | — | — | — |
| Shares out. | 2.8M | 9.4M | 9.4M | 418.3M | 402.2M | 180.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −8498.9%
- Net margin
- −8513.4%
- Return on equity
- 2599.5%
- Return on assets
- −814.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 131.3%
- Debt / equity
- —
- Book value / share
- $-0.19
- Revenue growth (YoY)
- 468.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -328.27distress
- Accruals / assets
- −552.1%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2015
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2011
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2011
- NT 10-Qmissed a reporting deadline ↗May 17, 2011
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Strome Mark EActivist (13D)Feb 27, 2026
- Hep Investments LlcActivist (13D)Mar 14, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Strome Mark E10% owner | Apr 17, 2026 | Buy | 100,000 | $2.00 |
| Yaldoo Laith LDirector | Feb 27, 2026 | Buy | 1,543 | $9.72 |
| Strome Mark E10% owner | Feb 12, 2026 | Buy | 20,000 | $9.77 |
| Yaldoo Laith LDirector | Feb 10, 2026 | Buy | 2,434 | $10.27 |
| Cornell Alison ADirector | Jan 26, 2026 | Buy | 11,709 | $8.54 |
| Payne John BernardOfficer — President and CEO | Jan 26, 2026 | Buy | 11,709 | $8.54 |
| Maggiore Christopher D.Director | Jan 14, 2026 | Buy | 1,766 | $8.49 |
| Yaldoo Laith LDirector | Jan 14, 2026 | Buy | 1,766 | $8.49 |
| Yaldoo Laith LDirector | Nov 28, 2025 | Buy | 2,777 | $9.00 |
| Strome Mark E10% owner | Oct 13, 2025 | Buy | 20,259 | $12.34 |
| Yaldoo Laith LDirector | Oct 10, 2025 | Buy | 1,659 | $12.05 |
| Maggiore Christopher D.Director | Oct 8, 2025 | Buy | 23,682 | $12.01 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8,871 | 1.5 | -36.0% |
| Apr 30, 2026 | 13,854 | 1.0 | -25.1% |
| Apr 15, 2026 | 18,505 | 1.1 | -55.0% |
| Mar 31, 2026 | 41,113 | 4.3 | -6.1% |
| Mar 13, 2026 | 43,778 | 63.2 | -0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureMar 30, 2026
- Director / officer changeDec 23, 2025
- Regulation FD disclosureSep 10, 2025
- Director / officer changeAug 18, 2025
- Entered a material agreement · New financial obligationJul 14, 2025
- Shareholder voteJun 11, 2025
- Unregistered equity saleJan 27, 2025
- Entered a material agreementJan 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Apr 24, 2026
- EFFECTApr 1, 2026
- 15-12GMar 31, 2026
- S-8 POSS-8Mar 31, 2026
- POS AMMar 31, 2026
- 8-KFORM 8-KMar 30, 2026
- 4PRIMARY DOCUMENTMar 3, 2026
- SCHEDULE 13D/AFeb 27, 2026
- 4Feb 17, 2026
- 4PRIMARY DOCUMENTFeb 12, 2026
- 4PRIMARY DOCUMENTJan 28, 2026
- 4PRIMARY DOCUMENTJan 28, 2026
- 4PRIMARY DOCUMENTJan 27, 2026
- 4PRIMARY DOCUMENTJan 27, 2026
- 3Dec 29, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.